MedDataX Logo

Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia

NCT ID: NCT03987880

Last Updated: 2020-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-22

Study Completion Date

2020-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the improvement in refractive error and the corneal endothelial safety with a customized corneal crosslinking treatment regimen for low grade myopia. The study compares two treatment protocols, a 4.0-mm central ring-shaped zone with a 3.5-mm central ring-shaped zone in high oxygen environment without corneal epithelial debridement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is a prospective, single-masked intraindividually comparing randomized controlled trial, conducted at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study includes healthy men and women with low grade myopia, aged between 18-35 years and involves 27 participants with a myopia of -0.5 to -2.5 diopters (D) and astigmatism of ≤0.75D. All participants are treated with phototherapeutic intrastromal corneal collagen cross-linking (PiXL) without epithelial debridement (epi-on), after topical riboflavin. Both eyes are treated and randomized to receive ultraviolet (UV) light according to PiXL 4.0 mm treatment zone in one eye and PiXL 3.5 mm treatment zone in the other, which is masked to the participant. For myopia \<0.75D, 10 J/cm\^2 is used and for higher levels of myopia 15J/cm\^2 is used. Throughout the treatment, humidified oxygen is continuously delivered around the eye using an oxygen mask to achieve an oxygen concentration of ≥95 percentage. All participants are informed about the procedures and provide oral and written consent before inclusion in the study.

At baseline, each eye is examined with slit-lamp microscopy, subjective refraction, determination of uncorrected (UCVA), low contrast visual acuity at 2.5 percentage and 10 percentage contrast and best corrected (BSCVA) visual acuities using the LogMAR fast protocol and intraocular pressure (IOP) using Goldmann applanation tonometry. Under standardized, mesopic light conditions each eye is evaluated by keratometry readings, central corneal thickness and after treatment also the depth of demarcation lines, extracted from Schemipflug camera measurements, Pentacam HR® (Oculus, Inc. Lynnwood, WA). Central corneal endothelial photographs are taken with the Topcon SP-2000P specular microscope (Topcon Europe B.V., Capelle a/d Ijssel, the Netherlands), from which the corneal endothelial cell count is manually calculated from a cluster of 25 cells from each photograph. Total ocular wavefront is measured with iTrace (Tracey Technologies, Inc.).

All the above mentioned examinations are reassessed at 1, 3 and 6 and 12 months after treatment. At 1 day and 1 week after treatment, solely UCVA, Auto refractor measurements, slit-lamp examination and a subjective comparison of discomfort and visual performance in each eye are evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia Corneal Crosslinking Refractive Errors Eye Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive ultraviolet (UV) light according to protocol A in one eye and protocol B in the other, which is masked to the participant. Both eyes will be treated during the same visit. Participants are randomized utilizing a computer list of unique random numbers between 1 and 27; an even number will be treated with the 4.0-mm zone in the right eye; an uneven number with the 4.0-mm zone in the left eye.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
The participants are not aware which eye will receive the 4.0-mm ring-shaped zone treatment and which eye will receive the 3.5-mm ring-shaped zone treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4.0 mm zone

PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.

Group Type ACTIVE_COMPARATOR

4.0 mm treatment

Intervention Type PROCEDURE

PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.

3.5 mm zone

PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.

Group Type EXPERIMENTAL

3.5 mm treatment

Intervention Type PROCEDURE

PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

4.0 mm treatment

PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.

Intervention Type PROCEDURE

3.5 mm treatment

PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Spherical equivalent on distance subjective refraction between -0.50D and -2.50D.

* Astigmatism ≤ 0.75D
* Stable myopia. Maximum change in refraction of 0.50D in the last 2 years.
* Best corrected visual acuity of at least 0.00 logMAR (ETDRS chart).
* Thinnest pachymetry reading ≥ 440 μm.
* No previous ocular surgery.
* No cognitive insufficiency interfering with the informed consent.

Exclusion Criteria

* History of or current condition, disease, surgery or medication with ocular effects that could affect the outcomes of the treatment.
* Allergy to any substance or device used in the study.
* Cognitive insufficiency interfering with the informed consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glaukos Corporation

INDUSTRY

Sponsor Role collaborator

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anders Behndig

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anders Behndig, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Sciences/Ophthalmology, Umeå University

Umeå, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PiXLMYOP-II

Identifier Type: -

Identifier Source: org_study_id